Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Alternext  >  Pharnext    ALPHA   FR0011191287

PHARNEXT (ALPHA)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
07/09/2018 07/10/2018 07/11/2018 07/12/2018 07/13/2018 Date
8.8(c) 8.84(c) 8.88(c) 8.8(c) 9.34(c) Last
959 9 494 1 953 5 011 27 949 Volume
-0.23% +0.45% +0.45% -0.90% +6.14% Change
More quotes
Financials (EUR)
Sales 2018 -
EBIT 2018 -18,7 M
Net income 2018 -18,8 M
Debt 2018 20,7 M
Yield 2018 -
Sales 2019 -
EBIT 2019 -20,9 M
Net income 2019 -20,9 M
Debt 2019 41,5 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 0
EV / Sales2019 0
Capitalization 106 M
More Financials
Company
Pharnext SA develops and manufactures drugs for neurological diseases.Its products include R&D Pipeline, PXT3003, and PXT864 are used for the treatment of Charcot-Marie-Tooth disease, diabetic, and toxic peripheral neuropathies, as well as severe neurodegenerative diseases in general and peripheral... 
More about the company
Latest news on PHARNEXT
07/11PHARNEXT : European Medicines Agency Agrees with Pharnexts Pediatric Investigati..
AQ
07/10PXT3003 : EMA agrees with Pharnext’s pediatric investigation plan
PU
07/10PHARNEXT : European Medicines Agency Agrees with Pharnext’s Pediatric Inve..
BU
06/23PHARNEXT : to Announce Top-Line Results from the Pivotal Phase 3 Trial of PXT300..
AQ
06/21PHARNEXT : to Announce Top-Line Results from the Pivotal Phase 3 Trial of PXT300..
BU
06/15PHARNEXT : Priority Review in China for Pharnext's PXT3003
AQ
06/15PHARNEXT : Announces PXT3003 was Granted Priority Review by the China Food and D..
AQ
06/14PXT3003 : Granted priority review by the China FDA
PU
06/14PHARNEXT : Announces PXT3003 was Granted Priority Review by the China Food and D..
BU
06/13PHARNEXT : Announces €20.5 Million Bond Loan
BU
More news
Sector news : Bio Therapeutic Drugs
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
07/10European Medicines Agency Agrees with Pharnext’s Pediatric Investigation Plan.. 
07/10European Medicines Agency Agrees with Pharnext’s Pediatric Investigation Plan.. 
06/24Pharnext to Announce Top-Line Results from the Pivotal Phase 3 Trial of PXT30..
1
06/14Pharnext Announces PXT3003 was Granted Priority Review by the China Food and .. 
06/14Pharnext Announces PXT3003 was Granted Priority Review by the China Food and .. 
More tweets
Qtime:59
Chart PHARNEXT
Duration : Period :
Pharnext Technical Analysis Chart | ALPHA | FR0011191287 | 4-Traders
Technical analysis trends PHARNEXT
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 15,4 €
Spread / Average Target 75%
EPS Revisions
Managers
NameTitle
Daniel Cohen Chief Executive Officer & Director
Michel de Rosen Chairman
Amit Kohli Chief Operating Officer
René Goedkoop Chief Medical Officer
Philippe Pouletty Director
Sector and Competitors
1st jan.Capitalization (M$)
PHARNEXT16.75%124
GILEAD SCIENCES8.01%100 614
VERTEX PHARMACEUTICALS20.45%45 997
REGENERON PHARMACEUTICALS-2.53%38 951
GENMAB5.49%10 457
NEUROCRINE BIOSCIENCES, INC.32.48%9 250